Charles River Laboratories International, Inc.

NYSE:CRL

Medical - Diagnostics & Research

Healthcare
$333.25 -1.33%

-$2.45 today

Market cap
$15.97B
Beta
1.45
P/E (TTM)
-48.3
EPS (TTM)
-$3.77
52W Low $144.26High $228.88

Volume 0.52M

Average 0.86M

CRL Accounts Payables

Cash effect of the change in amounts owed to suppliers; growing payables preserve cash.

Charles River Laboratories International, Inc.NYSE: CRL

Accounts Payables · Q2 FY2026 · quarter ended Jun 2026

Accounts payables turns positive

Q2 FY2026 accounts payables was $821K, compared with -$9.01M a year earlier. Trailing-twelve-month accounts payables was $7.9M.

Context

  • Accounts payables amounted to 0.1% of revenue in FY2025, down 0.3 pp from a year earlier.
  • Accounts payables increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly accounts payables holds near $821K or moves back toward the trailing-twelve-month quarterly average of $1.98M.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterJun 2026
$821K-96.0% QoQ
Last fiscal yearDec 2025
$2.87M+120.1% YoY
LTMJun 2026
$7.9M-6.0% YoY
Accounts Payables past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+109.1%——
1 year+120.1%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Accounts Payables history

USD · from the cash flow

Latest · FY2025
2.87M USD
Year-over-year change
+120.1%
4-year CAGR
-49.7%

Accounts Payables vs competitors

How CRL compares with its peers on the latest reported figures

  • CRL's LTM Jun 2026 accounts payables of $7.9M is the 2nd largest of the 4 companies compared; the peer median is $2.8M.
  • Its year-over-year change of -6.0% is the lowest of 3, against a peer median of +122.2%.
  • Accounts payables amounts to 0.2% of revenue for CRL, versus a peer median of 0.1%.
CRL Competitors Peer median
Accounts Payables for CRL and competitors
Company Period LTM YoY 3-year CAGR% of revenue
CERTCertara, Inc.LTM Mar 2026$10.67M +138.4%—2.5%
CRLCharles River Laboratories International, Inc.LTM Jun 2026$7.9M -6.0%—0.2%
MEDPMedpace Holdings, Inc.LTM Sep 2026$2.8M +106.0%-25.8%0.1%
ICLRICON Public Limited CompanyLTM Jun 2026$0 ——0.0%
Peer median (excluding CRL) $2.8M+122.2%-25.8%0.1%

Competitors are the stored peer set for CRL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income398.84M492.61M480.37M25.29M(142.16M)
Depreciation & Amortization265.54M303.87M314.12M361.74M403.31M
Deferred Income Tax(24.01M)(35.88M)(50.9M)(67.43M)(75.29M)
Stock-Based Compensation71.47M73.62M72.05M69.89M71.08M
Change in Working Capital42.94M(152.55M)(102.38M)(30.33M)14.08M
Accounts Receivables(26.63M)(150.57M)(33.43M)21.61M35.74M
Inventory(25.16M)(78.52M)(62.3M)16.8M(48.78M)
Accounts Payables44.9M(2.65M)(20.43M)(14.27M)2.87M
Other Working Capital49.83M79.19M13.78M(54.47M)24.25M
Other Non-Cash Items6.01M(62.02M)(29.36M)375.41M466.63M
Operating Cash Flow760.8M619.64M683.9M734.58M737.65M
Capital Expenditures(228.77M)(324.73M)(318.53M)(232.97M)(219.15M)
Acquisitions (Net)(1.17B)(120.12M)(194.79M)(5.48M)17.44M
Purchases of Investments(45.56M)(158.27M)(54.22M)(52.88M)(20.08M)
Sales of Investments6.53M4.55M6.67M41.69M9.1M
Other Investing Activities264K(9.35M)(2.29M)4.55M3.36M
Investing Cash Flow(1.44B)(607.92M)(563.16M)(245.09M)(209.32M)
Debt Repayment669.98M19.79M(75.32M)(412.19M)(121.78M)
Common Stock Issued0000714K
Common Stock Repurchased(40.71M)(38.65M)(24.16M)(119.18M)(360.67M)
Dividends Paid00000
Other Financing Activities43.32M(23.54M)13.96M(19.56M)(54.98M)
Financing Cash Flow672.6M(42.4M)(85.52M)(550.93M)(536.73M)
Effect of Forex Changes17.73M25.58M8.04M(17.47M)18.83M
Net Change in Cash13.2M(5.1M)43.27M(78.91M)10.43M
Free Cash Flow532.03M294.91M365.37M501.61M518.49M

Charles River Laboratories International, Inc.

NYSE:CRL

Intrinsic Alpha fair value

Locked

Current Price

$333.25

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.